Research Bcell
Related Resources for this page:
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER Signaling
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Targeting cancers with ADCs
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Antibody-Drug conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- The evolving CLL treatment landscape
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Emerging therapeutic options
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Antibody-Drug Conjugates
Share
Activation of cell proliferation signals in the development of cancer
- Cell growth and proliferation can be activated by extracellular growth factors. Many of these growth factors bind to cell surface tyrosine kinase receptors (TKRs)1,12
- Activation of intracellular signal transduction pathways ultimately results in altered gene expression and increased cellular growth/proliferation (Figure 4)1,12
- In many tumor types, dysregulation of TKRs and/or their downstream signal transduction pathways has been shown to play a role in oncogenesis1
- Blocking cellular proliferation signals by targeting TKRs or their intracellular signal transduction pathways has been an important strategy in the current treatment of several tumor types. This approach remains under exploration in the development of newer anticancer therapies12
